Please login to the form below
Epogen
The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Epogen was produced by Amgen.
AZ preps new roxadustat filings, though data foxes investors
Epoetin alfa is sold by Amgen as Epogen and Janssen as Procrit, but these brands were joined by Pfizer’s lower-cost biosimilar Retacrit last year.
China first market to approve AZ’s kidney drug roxadustat
as Amgen’s Epogen (epoetin alfa) and Aranesp (darbepoetin alfa).
Pfizer gets FDA panel recommendation for biosimilar EPO
Product could be the first direct competitor to Epogen and Procrit in the US. ... If the FDA follows its panel's advice – which it generally does – Pfizer will have a direct competitor to Amgen's Epogen and Johnson &Johnson Procrit blockbuster brands
Novartis gets FDA panel backing for biosimilar Enbrel
The company has several other biosimilars in clinical development, including copycat versions of Humira, Roche's MabThera/Rituxan (rituximab), Amgen's Epogen (epoetin alfa) and Neulasta (pegfilgrastim) and Johnson &Johnson's
Amgen biosimilar matches AbbVie's Humira in psoriasis trial
to its own drugs such as Neupogen (filgrastim) and Epogen (epoetin alfa) in Europe. .
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- How COVID-19 is accelerating the threat of antimicrobial resistance
- UK COVID-19 vaccine ‘challenge trials’ could intentionally infect participants with virus
- FDA hands BMS and bluebird bio a priority review for ide-cel
- Lilly’s Verzenio scores a win in early-stage breast cancer
- Keytruda doubles five-year survival rate in NSCLC
- Live Webinar: Leveraging Digital Technologies to Create Valuable KOL Engagements & Empower Patients
- Live Webinar: Harnessing Technology to Improve Health and Healthcare
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Lilly’s Verzenio scores a win in early-stage breast cancer
- FDA sets January decision date for Xalkori in ALK-positive lymphoma
- Q&A: Isabel Gibson
PMHub
Empowering Strategic Performance Ltd
OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...
Latest intelligence
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
- Are patient recruitment and retention rates rising or falling?
- First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Quick links
Infographics
